AMENDMENTS TO THE CLAIMS

1-20. (Canceled).

Claim 21 (Currently Amended): A compound of formula I



I

where:

m is an integer selected from 0, 1, and 2;

n and o are integers independently selected from 0 and 1;

A is selected from the group consisting of N and CH;

B is selected from the group consisting of $-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-C(=O)-NH-$, $-C(=O)-CH_2-$, $-CH_2-C(=O)-NH-$, $-C(=O)-CH_2-C(=O)-$, $-C(=O)-NH-CH_2-$, $-C(=O)-$, $-S(=O)-$, $-S(=O)_2-$, $-S(=O)-NH-$, $-S(=O)_2-NH-$, $-S(=O)-CH_2-$, $-S(=O)_2CH_2-$, $-S(=O)-CH_2-NH-$, $-S(=O)_2-CH_2-NH-$, $-S(=O)_2-NH-CH_2-$, $-CH_2-S(=O)_2-NH-$, $-C(=O)-NH-S(=O)_2-$, $-S(=O)_2-NH-C(=O)-$, $-C(=O)-CH_2-S(=O)_2-$, and $-S(=O)_2-CH_2-C(=O)-$;

J is absent or selected from the group consisting of –O-, -S-, $-CHR^{15}-O-$, $-CH_2-CHR^{15}-O-$, -NH-, $-NH-CHR^{15}-$, [-NH-(C_2-C_6alkyl)-;] $-NH-CHR^{15}-C(=O)-$, $-C(=O)-$, $-CH_2-$, $-CHR^{15}-CH_2-NH-$, $-C(=O)-CHR^{15}-$, $-NH-C(=O)-CH(C_1-C_6alkyl)-$, $-NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-$, $-CH_2CH_2-$, $-CH_2NH-$, $-CH_2-NH-C(=O)-$, $-CH_2-NH-C(=O)-C_1-C_6alkyl-$, $-CH_2-NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-$ and $-C(=O)-CHR^{15}-NH-$; or

B-J is selected from the group consisting of $-C(=O)-CH_2-NH-C(=O)-CH(C_1-C_6alkyl)-$, $-C(=O)-CH_2-NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-$, $-C(=O)-NH-(C_2-C_6alkyl)-$, $-S(=O)_2-NH-(C_2-C_6alkyl)-$, $-C(=O)-NH-$, $-S(=O)_2-NH-$, $-C(=O)-CH-$ and $-S(=O)-CH_2-$;

L is selected from the group consisting of –O-, $–CH_2-O-$, $-O-CH_2-$, $-CH_2-CH_2-O-$, $-O-CH_2-CH_2-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, -C(=O)-NH-, -O-C(=O)-NH-, $-CH_2-C(=O)-NH-$, $-C(=O)-CH_2-NH-$, $-C(=O)-NH-CH_2-$, -NH-C(=O)-, NH-C(=O)-O-, $-NH-CH_2-C(=O)-$, $-NH-C(=O)-CH_2-$, $-CH_2-NH-C(=O)-$, -NH-C(=O)-NH-, $-NH-S(=O)_2-NH-$, $-NH-S(=O)_2-$, $-NH-S(=O)_2-CH_2-$, $-CH_2-NH-S(=O)_2-$, $-S(=O)_2-NH-$, $-S(=O)_2-NH-CH_2-$, $-CH_2-S(=O)_2-NH-$, $-C(=O)-NH-S(=O)_2-$, $-S(=O)_2-NH-C(=O)-$, $-CH_2-NH-$, $-CH_2-CH_2-NH-$, $-NH-CH_2-$, $-NH-CH_2-CH_2-$, $-CH_2-NH-CH_2-$, -C≡C-, $-CH_2-C≡C-$, $-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-$, $-CH_2-CH=CH-$, $CH=CH-CH_2-$, and –CH=CH-;

M is selected from the group consisting of R^9,



and ;

Q is selected from the group consisting of $-C(=O)OR^{16}$, -C(=O)-NH-C(=O)-CF_3, -C(=O)-NH-$S(=O)_2$-R^2, -C(=O)-NR^1-OH, 5-oxo-4,5-dihydro[1,2,4]oxadiazol-3-yl, and tetrazolyl;

X is A when n is 1, and is CH, N, O or S when n is 0;

R^1 is selected from the group consisting of hydrogen, (C_1-C_6)alkyl, halo-(C_1-C_6)alkyl, and (C_3-C_6)cycloalkyl;

R^2, R^3 and R^5 are individually selected from the group consisting of hydrogen, cyano, nitro, phenyl, phenoxy, benzyl, C_1-C_6alkyl, halo, halo-C_1-C_6alkyl, C_3-C_6cycloalkyl, C_1-C_6alkoxy, hydroxy, C_1-C_2alkoxy-methoxy, hydroxy-C_1-C_6alkyl, formyl, C_1-C_6alkylcarbonyl, amino, C_1-C_6alkylamino, aminocarbonyl, C_1-C_6alkylaminocarbonyl, formylamino, and C_1-C_6alkylcarbonylamino, where any alkyl or phenyl may optionally be substituted with halo or Q;

R^4 is selected from the group consisting of R^2 and 

where Ar is a homo- or hetero-aryl group having 1 or 2 rings, each ring containing 5, 6 or 7 ring atoms of which 1-3 may be heteroatoms selected from N, O and S;

R^6 is selected from the group consisting of hydrogen, C_1-C_6alkyl, halo, halo-C_1-C_6alkyl, C_3-C_6cycloalkyl, C_1-C_6alkoxy, C_1-C_6alkoxy-C_1-C_6alkyl, hydroxy, hydroxy-C_1-C_6alkyl, HC(=O)-C_1-C_6alkyl, carboxy, carboxy-C_1-C_6alkyl, carbonylamino-C_1-C_6alkyl, aminocarbonyl, (C_1-C_6alkyl)aminocarbonyl, di(C_1-C_6alkyl)aminocarbonyl, and aminocarbonyl-C_1-C_6alkyl;

R^7 is selected from the group consisting of hydrogen, C_1-C_6 alkyl, halo, halo-C_1-C_6alkyl, C_3-C_6cycloalkyl, C_1-C_6alkoxy, C_1-C_6alkoxy-C_1-C_6alkyl, hydroxy, hydroxy-C_1-C_6alkyl, HC(=O)-C_1-C_6alkyl, carboxy, carboxy-C_1-C_6alkyl, carbonylamino-C_1-C_6alkyl, aminocarbonyl, (C_1-C_6alkyl)aminocarbonyl, di(C_1-C_6alkyl)aminocarbonyl, and aminocarbonyl-C_1-C_6alkyl;

$R^{7'}$ is hydrogen; or

R^7 and $R^{7'}$ together with the carbon to which they are bonded form –C(=O)-;

R^8 is selected from the group consisting of hydrogen, hydroxy, C_1-C_6alkoxy, C_1-C_6alkyl, halo, halo-C_1-C_6alkyl, and C_3-C_6cycloalkyl;

R^9 is selected from the group consisting of–$NR^{10}R^{11}$, -C(=NR^{12})-NHR^{13}, -N=CR^{14}-$NR^{10}R^{11}$, -NR^{13}-CR^{14}=NR^{12}, and -NR^{13}-C(=NR^{12})-NHR^{13}[, =NH, and -CH=NH];

R^{10}, R^{11}, R^{12}, R^{13} and R^{14} are independently selected from the group consisting of hydrogen, hydroxy, hydroxy-C_1-C_6alkyl, C_1-C_6alkyl, halo-C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkoxy-C_1-C_6alkyl,

and C_3-C_7 cycloalkyl; or any member of the group R^{10}, R^{11}, R^{12}, and R^{13}[, and R^{14}] together with the nitrogen to which it is attached forms a 5, 6 or 7 member heterocycle with any other member of the group, the heterocycle optionally containing one additional heteroatom selected from N, O and S;

R^{15} is selected from the group consisting of hydrogen, C_1-C_{12}alkyl, C_3-C_7cycloalkyl, aminocarbonyl, C_1-C_6alkylaminocarbonyl, and di(C_1-C_6alkyl)aminocarbonyl; and

R^{16} is selected from the group consisting of hydrogen, C_1-C_6alkyl, C_3-C_{13}cycloalkyl, C_6-C_{10}aryl, acetylamino-C_1-C_{12}alkyl, C_1-C_6alkylcarbonyloxy-C_1-C_6alkyl, and C_6-C_{10}aryl-C_0-C_6alkylcarbonyloxy-C_1-C_6alkyl,

or a pharmaceutically acceptable salt thereof.

Claim 22 (Previously Presented): The compound of claim 21 that is a compound of formula II



II

where the substituents are defined as in claim 21;

or a pharmaceutically acceptable salt thereof.

Claim 23 (Currently Amended): The compound of claim 22 that is a compound of formula III or formula III':



III



III'

where the substituents are as defined in claim 21,

or a pharmaceutically acceptable salt thereof.

Claim 24 (Withdrawn): The compound of claim 21 that is a compound of formula IV



IV

where the substituents are as defined in claim 21,

or a pharmaceutically acceptable salt thereof.

Claim 25 (Previously Presented): The compound of claim 21 where R^1 is hydrogen or C_1-C_6alkyl.

Claim 26 (Previously Presented): The compound of claim 21 where R^2 and R^3 are hydrogen, C_1-C_6alkyl, cyano, or halo.

Claim 27 (Previously Presented): The compound of claim 21 where B is –C(=O)- or –$S(=O)_2$-.

Claim 28 (Previously Presented): The compound of claim 21 where J is –CH_2-, -CH_2-CH_2-, -NH-, -NH-CH_2-, -CH_2-NH-, -CH_2-NH-C(=O)-, -CH_2-NH-C(=O)-C_1-C_6alkyl- or -CH_2-NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-.

Claim 29 (Previously Presented): The compound of claim 21 where B-J is selected from the group consisting of –C(=O)-CH_2-NH-C(=O)-CH(C_1-C_6alkyl), -C(=O)-CH_2-NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-, -C(=O)-NH-(C_2-C_6alkyl), -$S(=O)_2$-NH-(C_2-C_6alkyl)-, -C(=O)-NH-, -$S(=O)_2$-NH-, -C(=O)-CH_2- and –$S(=O)_2$-CH_2-.

Claim 30 (Currently Amended): A compound of formula II



II

where:

A is selected from the group consisting of N and CH;

B is –C(=O)- or –$S(=O)_2$-;

J is –CH_2-, -CH_2-CH_2-, -NH-, -NH-CH_2-, -CH_2-NH-, -CH_2-NH-C(=O)-, -CH_2-NH-C(=O)-C_1-C_6alkyl-, or –CH_2-NH-C(=O)-CH(C_3-C_{12}cycloalkyl)-;

M is selected from the group consisting of





and



;

R^1 is hydrogen or C_1-C_6 alkyl;

R^2 and R^3 are hydrogen, C_1-C_6alkyl, cyano, or halo;

R^4 is hydrogen, C_1-C_6alkyl, cyano, halo or 

where Ar is phenyl, furyl, thienyl, oxazolyl, thiazolyl, or pyrrolyl;

R^5 is hydroxy or C_1-C_3alkoxy;

L is selected from the group consisting of –O-, $–CH_2$-O-, -O-CH_2-[, or -CH_2-CH_2-] and -CH_2CH_2O-;

Q is selected from the group consisting of $–C(=O)OR^{16}$, -C(=O)-NH-C(=O)-CF_3, -C(=O)-NH-S(=O)$_2$-R^2, -C(=O)-NR^1-OH, 5-oxo-4,5-dihydro[1,2,4]oxadiazol-3-yl, and tetrazolyl;

R^6 is selected from the group consisting of hydrogen, C_1-C_6alkyl, halo, halo-C_1-C_6alkyl, C_3-C_6cycloalkyl, C_1-C_6alkoxy, C_1-C_6alkoxy-C_1-C_6alkyl, hydroxy, hydroxy-C_1-C_6alkyl, HC(=O)-C_1-C_6alkyl, carboxy, carboxy-C_1-C_6alkyl, carbonylamino-C_1-C_6alkyl, aminocarbonyl, (C_1-C_6alkyl)aminocarbonyl, di(C_1-C_6alkyl)aminocarbonyl, and aminocarbonyl-C_1-C_6alkyl;

R^7 is selected from the group consisting of hydrogen, C_1-C_6 alkyl, halo, halo-C_1-C_6alkyl, C_3-C_6cycloalkyl, C_1-C_6alkoxy, C_1-C_6alkoxy-C_1-C_6alkyl, hydroxy, hydroxy-C_1-C_6alkyl, HC(=O)-C_1-C_6alkyl, carboxy, carboxy-C_1-C_6alkyl, carbonylamino-C_1-C_6alkyl, aminocarbonyl, (C_1-C_6alkyl)aminocarbonyl, di(C_1-C_6alkyl)aminocarbonyl, and aminocarbonyl-C_1-C_6alkyl;

$R^{7'}$ is hydrogen; or

R^7 and $R^{7'}$ together with the carbon to which they are bonded form –C(=O)-;

R^8 is selected from the group consisting of hydrogen, hydroxy, C_1-C_6alkoxy, C_1-C_6alkyl, halo, halo-C_1-C_6alkyl, and C_3-C_6cycloalkyl;

[R^9 is selected from the group consisting of $–NR^{10}R^{11}$, -C(=NR^{12})-NHR^{13}, -N=CR^{14}-$NR^{10}R^{11}$, -NR^{13}-CR^{14}=NR^{12}, -NR^{13}-C(=NR^{12})-NHR^{13}, =NH, and -CH=NH;

R^{10}, R^{11}, R^{12}, R^{13} and R^{14} are independently selected from the group consisting of hydrogen, hydroxy, hydroxy-C_1-C_6alkyl, C_1-C_6alkyl, halo-C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkoxy-C_1-C_6alkyl, and C_3-C_7 cycloalkyl; or any member of the group R^{10}, R^{11}, R^{12}, R^{13}, and

R^{14} together with the nitrogen to which it is attached forms a 5, 6 or 7 member heterocycle with any other member of the group, the heterocycle optionally containing one additional heteroatom selected from N, O and S]; and

R^{16} is selected from the group consisting of hydrogen, C_1-C_6alkyl, C_3-C_{13}cycloalkyl, C_6-C_{10}aryl, acetylamino-C_1-C_{12}alkyl, C_1-C_6alkylcarbonyloxy-C_1-C_6alkyl, and C_6-C_{10}aryl-C_0-C_6alkylcarbonyloxy-C_1-C_6alkyl,

or a pharmaceutically acceptable salt thereof.



Claim 31 (Currently Amended): The compound claim 30 that is a compound of formula III'



Claim 32 (Previously Presented): A composition comprising a compound of claim 21 or 30 and a pharmaceutically acceptable excipient.

Claim 33 (Previously Presented): A method of treating a mammal having a disease for which the antagonism of IL-2/IL-2R binding is indicated, comprising administering to the mammal a therapeutically effective dose of a compound of claim 21 or 30.

Claim 34 (Previously Presented): The method of claim 33 where the disease is T-lymphocyte-induced rejection of an allograft.

Claim 35 (Previously Presented): The method of claim 34 where T-lymphocytes which express IL-2R in response to antigens of the allograft are contacted with the compound.

Claim 36 (Previously Presented): The method of claim 34 where the allograft is a skin allograft.

Claim 37 (Previously Presented): The method of claim 34 where the allograft is a transplanted organ.

Claim 38 (Previously Presented): The method of claim 37 where the transplanted organ is a heart.

Claim 39 (Previously Presented): The method of claim 33 where the disease is an autoimmune disease.

Claim 40 (Previously Presented): The method of claim 39 where the autoimmune disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, uveitis, and psoriasis.